-

Thermo Fisher Scientific Releases Corporate Social Responsibility Report

Report highlights progress toward environmental, social and governance objectives

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today released its annual Corporate Social Responsibility (CSR) report. The report highlights the company’s commitment to society and stakeholders providing detailed insight into the company’s CSR progress and environmental, social and governance (ESG) efforts.

“Our Mission to enable our customers to make the world healthier, cleaner and safer guides all of our actions,” said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. “Reducing our impact on the environment, fostering an inclusive culture and being active members of our communities gives our more than 100,000 colleagues the opportunity to make a difference every day.”

Highlights from the company’s annual CSR report include:

Environment

  • Achieved 12% reduction in absolute Scope 1 and 2 emissions compared to 2018, putting the company ahead of schedule towards its 2030 target to reduce Scope 1 and 2 greenhouse gas emissions by 30%, even as it expanded global capacity in 2020 and 2021.
  • Committed to net-zero emissions across its value chain by 2050, aligning the company’s climate strategy and goals with the Paris Agreement, and expanding on its existing 2030 target.

Operations

  • Increased direct and indirect spending with small and traditionally underrepresented businesses from $1.3 billion to $2.0 billion. This is part of a Supplier Diversity Program designed to proactively promote more inclusive procurement practices that reflect the company’s customer base, employees and communities.
  • Continued mobilization of company resources to accelerate development, manufacturing and distribution of products critical to the global pandemic response, becoming one of the largest testing suppliers to global relief organizations for use in more than 100 low- and middle-income countries.

Communities

  • Reached more than 100,000 students and 6,600 educators through science, technology, engineering and math (STEM) programming across 21 countries.
  • Volunteered more than 105,000 hours worldwide through local Community Action Councils.

Colleagues

  • Advanced its diversity and inclusion strategy including demonstrated progress in improving representation within company leadership positions.

In reporting our CSR progress, the company considers internationally recognized standards, guidelines and reference frameworks including the Global Reporting Initiative (GRI) Sustainability Reporting Standards, United Nations Sustainable Development Goals (SDGs), the Value Reporting Foundation’s SASB Standards and the Task Force on Climate-related Financial Disclosures (TCFD). The company makes additional topic-specific ESG data available through CDP, EcoVadis, and the voluntary disclosure of its annual EEO-1 information.

Learn more at www.thermofisher.com/csr

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Media Contact Information:
Ron O’Brien
Phone: 781-622-1242
E-mail: ron.obrien@thermofisher.com

Investor Contact Information:
Rafael Tejada
Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com

Thermo Fisher Scientific Inc.

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Versions

Contacts

Media Contact Information:
Ron O’Brien
Phone: 781-622-1242
E-mail: ron.obrien@thermofisher.com

Investor Contact Information:
Rafael Tejada
Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com

More News From Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Launches Applied Biosystems™ PowerFlex™ Thermal Cycler to Advance PCR Flexibility and Productivity

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the Applied Biosystems™ PowerFlex™ Thermal Cycler, a next-generation polymerase chain reaction (PCR) instrument designed to help deliver enhanced flexibility, precise thermal performance and improved productivity for modern molecular biology laboratories. Building on the trusted legacy of Applied Biosystems™ instruments, this solution is designed to help laboratories run complex...

Thermo Fisher Scientific’s PPD Clinical Research Business Collaborates with HealthVerity to Expand Real-World Data Capabilities

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced a strategic data collaboration with HealthVerity, a leading real-world data (RWD) marketplace, to enhance data-driven clinical development and evidence generation for biopharma sponsors. Through the agreement, Thermo Fisher’s PPD™ clinical research business will gain enterprise-level access to HealthVerity’s TaXOnomy® claims dataset, representing more than 270 million de-identified pa...

Thermo Fisher Scientific Expands Global Biobank Leadership Through Strategic Collaboration with PRECISE-SG100K Singapore to Advance Population-Scale Proteomics

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced a strategic collaboration with Precision Health Research, Singapore (PRECISE) to advance the PRECISE-SG100K study, one of the region’s most ambitious and diverse population-scale biobank initiatives. The collaboration reflects growing investments from national population studies looking to harness proteomics to drive insight into real-time disease biology for applicat...
Back to Newsroom